Re-reading this (this is big, big stuff happening!
Post# of 15624
(Total Views: 304)
Posted On: 03/08/2017 10:00:17 PM
Re-reading this (this is big, big stuff happening!)
8.2 One World Cannabis Signs Agreement with Sheba Academic Medical Center
OWC Pharmaceutical Research Corp.’s wholly owned subsidiary One World Cannabis, Ltd. signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East. Within the framework of a new collaboration agreement, the company will initiate a study to explore the effect of several combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma, starting with a basic science on multiple myeloma cells.
Multiple myeloma, a cancer of plasma cells, accounts for 10% of all hematologic malignancies. It is the second most common hematologic cancer and represents 1% of all cancer diagnoses and 2% of all cancer deaths. The study will be conducted at the Sheba Academic Medical Center facilities, composed of a highly diverse yet interactive collaborative team of molecular biologists, immunologists, cell biologists and clinicians, located in Ramat Gan (near Tel Aviv), Israel.
The Chaim Sheba Academic Medical Center at Tel Hashomer, Israel (near Tel Aviv), is the largest and the most comprehensive medical center in Israel and the Middle East, recognized internationally for its leadership in clinical treatment, as well as basic and applied medical research. It is situated on a 150-acre campus at Tel Hashomer on the outskirts of Tel Aviv. It is the teaching center for Tel Aviv University’s medical and nursing schools, and is home to Israel’s national institutes of health, central blood bank, and military rehabilitation facilities.
Petah Tikva’s One World Cannabis is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OWCP 11.03)
8.2 One World Cannabis Signs Agreement with Sheba Academic Medical Center
OWC Pharmaceutical Research Corp.’s wholly owned subsidiary One World Cannabis, Ltd. signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East. Within the framework of a new collaboration agreement, the company will initiate a study to explore the effect of several combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma, starting with a basic science on multiple myeloma cells.
Multiple myeloma, a cancer of plasma cells, accounts for 10% of all hematologic malignancies. It is the second most common hematologic cancer and represents 1% of all cancer diagnoses and 2% of all cancer deaths. The study will be conducted at the Sheba Academic Medical Center facilities, composed of a highly diverse yet interactive collaborative team of molecular biologists, immunologists, cell biologists and clinicians, located in Ramat Gan (near Tel Aviv), Israel.
The Chaim Sheba Academic Medical Center at Tel Hashomer, Israel (near Tel Aviv), is the largest and the most comprehensive medical center in Israel and the Middle East, recognized internationally for its leadership in clinical treatment, as well as basic and applied medical research. It is situated on a 150-acre campus at Tel Hashomer on the outskirts of Tel Aviv. It is the teaching center for Tel Aviv University’s medical and nursing schools, and is home to Israel’s national institutes of health, central blood bank, and military rehabilitation facilities.
Petah Tikva’s One World Cannabis is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OWCP 11.03)
(3)
(0)